Welcome to the e-CCO Library Archive!

search
                             
search by: 
Filter:
DOP054.

Predictors of phenotype progression in Crohn's disease

Authors:

E. Rodrigues-Pinto, F. Magro, R. Coelho, P. Andrade, J. Santos-Antunes, S. Lopes, G. Macedo, Centro Hospitalar São João, Gastroenterology Department, Porto, Portugal

DOP054

DOP054 has been converted to a hard copy poster presentation upon author’s request – please refer to p. 222 (P289a)

DOP055.

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease

Authors:

J.M. Semmler1, A. Pilch1, F.P. Armbruster1, A. Dignass2, W. Kruis3, J. Stein4, 1Immundiagnostik, AG, Bensheim, Germany, 2Agaplesion Markus Hospital, Department of Medicine I, Frankfurt, Germany, 3Ev. Krankenhaus, Med. Klinik, Köln, Germany, 4Crohn Colitis Center, DGD Krankenhaus Sachsenhausen, Frankfurt, Germany

DOP055

Combination therapy with infliximab and azathioprine improves Crohn's disease outcome and infliximab tolerance compared to infliximab therapy alone

Authors:

G. Pineton de Chambrun*1, L. Libier2, M. Collins3, M. Nachury2, D. Koriche4, C. Gower-Rousseau5, P. Zerbib4, A. Cortot6, J.-F. Colombel7, P. Desreumaux2

1Montpellier 1 University, Gastroenterology and Hepatology, Montpellier, France, 2CHU de Lille, Department of Gastroenterology, Lille, France, 3APHP Paris Sud University , Gastroenterology, Le Kremlin Bicêtre, France, 4Lille University Hospital, Colorectal Surgery Department , Lille, France, 5Lille University Hospital, North of France University, Epidemiology, Lille, France, 6Lille University Hospital, North of France University, Gastroenterology, Lille, France, 7Mount Sinai Hospital, Gastroenterology, New-York, United States

DOP056.

Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases

Authors:

X. Roblin1, M. Rinaudo2,3, E. del Tedesco1, J.M. Phelip1, L. Peyrin Biroulet4, S. Paul3, 1University Hospital, Gastroenterology, Saint Etienne, France, 2University Hospital, Immunology, Saint Etienne, France, 3University of Saint Etienne, Immunology, Saint Etienne, France, 4Brabois Hospital, Gastroenterology, Vandoeuvre les Nancy, France

DOP056

Long-term outcomes of top-down versus step-up treatment in newly diagnosed Crohn's disease: final data

Authors:

D. Hoekman*1, J. Stibbe1, F. Baert2, P. Caenepeel3, P. Vergauwe4, M. de Vos5, A. van Bodegraven6, S. Vermeire3, G. D'Haens1

1Academic Medical Center, Department of Gastroenterology, Amsterdam, Netherlands, 2H.-Hartziekenhuis - AZ Delta, Gastroenterology, Roeselare, Belgium, 3Katholieke Universiteit and University Hospital Gasthuisberg, Division of Gastroenterology, Leuven, Belgium, 4AZ Groeninge, Gastroenterology, Kortrijk, Belgium, 5Ghent University Hospital, Department of Gastroenterology, Ghent, Belgium, 6ORBIS Medical Centre, Gastroenterology and Hepatology, Sittard, Netherlands

DOP057.

The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF-α levels and clinical outcome

Authors:

G. Bodini1, V. Savarino1,2, P. Dulbecco1,3, I. Baldissarro1,2, E. Savarino1,4,5, 1IRCCS San Martino Genova, Dipartimento di medicina interna, Genova, Italy, 2Universita di Genova, Dipartimento di medicina interna, Genova, Italy, 3Università di Genova, Dipartimento di Medicina Interna, Genova, Italy, 4University of Padua, Department of Surgery, Oncology and Gastroenterology, padova, Italy, 5Department of Surgery, Oncology and Gastroenterology, University of Padua, gastroenteroly unit, padua, Italy

DOP057

Evolution of the Lémann Index (LI) during the course of Crohn's disease (CD)

Authors:

C. Gilletta1, M. Lewin2, P. Seksik1, A. Bourrier3, I. Nion-Larmurier4, H. Sokol2, L. Beaugerie5, B. Pariente6, J. Cosnes*1

1hopital St-Antoine, Gastroenterology, Paris, France, 2Hopital Saint-Antoine - APHP, Department of Gastroenterology, Paris, France, 3Hopital St Antoine , Gastroenterology , Paris, France, 4Hopital Saint Antoine, Gastroenterology , Paris, France, 5hopital saint-antoine, gastroenterology, Paris, France, 6CHU Lille, Gastroenterology, Lille, France

DOP058.

Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studies

Authors:

M. Rosario1, T. Wyant2, C. Milch3, A. Parikh4, B. Feagan5, W.J. Sandborn6, H. Yang7, I. Fox1, 1Takeda Pharmaceuticals International Company, Clinical Pharmacology, Cambridge, United States, 2Takeda Pharmaceuticals International Company, Translational Medicine, Cambridge, United States, 3Takeda Pharmaceuticals International Company, Clinical Research, Cambridge, United States, 4Takeda Pharmaceuticals International, Inc., General Medicine, Deerfield, United States, 5University of Western Ontario, Department of Epidemiology and Biostatistics, London, Canada, 6University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 7Takeda Pharmaceuticals International Company, Statistics, Cambridge, United States

DOP058

Long-term outcome of infliximab treatment in patients with Crohn's disease: a hospital-based cohort study from Korea

Authors:

S.H. Park*, S.-K. Yang, J.H. Bae, S. Lee, J.S. Soh, H.-S. Lee, H.J. Lee, D.-H. Yang, B.D. Ye, J.-S. Byeon, K.-J. Kim, S.-J. Myung, J.-H. Kim, K. Chang, H. Seo, H. So, M.S. Kwak

University of Ulsan College of Medicine, Asan Medical Center, Gastroenterology, Seoul, Korea, Republic of

DOP059.

Reduction of fecal calprotectin levels and relationship to clinical parameters in the phase 2 study of laquinimod for the treatment of active moderate to severe Crohn's disease

Authors:

G. D'Haens1, W.J. Sandborn2, P. Rutgeerts3, J.F. Colombel4, K. Brown5, A. Haviv6, H. Barkay7, A. Sakov7, B. Feagan8, 1University of Amsterdam, Academic Medical Center, Amsterdam, Netherlands, 2University of California, UCSD Inflammatory Bowel Disease Center, San Diego CA, United States, 3Catholic University of Leuven, Department of Internal Medicine and Endoscopy, Leuven, Belgium, 4Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, 5Teva Pharmaceuticals, Clinical Development Research and Development, Frazer, United States, 6Chiasma Pharm, Formerly of Teva Pharmaceuticals, Jerusalem, Israel, 7Teva Pharmaceuticals, Biostatistics Research and Development, Netanya, Israel, 8University of Western Ontario, Robarts Clinical Trials Robarts Research Institute, Ontario, Canada

DOP059

Clinical predictive parameters for severe Crohn's disease in real-life: Results from EPIC, a nation-wide prospective observational study

Authors:

C. Schmidt*1, B. Bokemeyer2, U. Helwig3, A. Luegering4, N. Teich5, K. Engel6, S. Rath6, B.M. Wittig6, A. Stallmach1

1Jena University Hospital, Clinic for Internal Medicine IV, Jena, Germany, 2Gastroenterology Practice, Minden, Germany, 3Gastroenterology Practice, IPO, Oldenburg, Germany, 4Gastroenterology Practice, Muenster, Germany, 5Internistische Gemeinschaftspraxis, Leipzig, Germany, 6AbbVie Deutschland GmbH & Co. KG, Medical Department, Wiesbaden, Germany

DOP060.

CD62L (L-selectin) shedding for assessment of functional blockade of TNF alpha in anti-TNF treated inflammatory bowel disease patients: clinical feasibility and perspectives

Authors:

P. Juillerat1,2, P. Andrew1, J. Macpherson1, E. Slack1, N. Patuto1,2, J. Cahenzli1, K.D. McCoy1, A.J. Macpherson1,2, 1University Bern, Maurice E Müller Laboratories, Universitätsklinik für Viszerale Chirurgie und Medizin, Inselspital, Bern, Switzerland, 2Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland

DOP060

Long-term outcome of IBD patients with primary non-response to anti-TNF therapy

Authors:

K. Papamichail*1, 2, O. Rivals3, T. Billiet1, M. Ferrante1, G.A. Van Assche1, P.J. Rutgeerts1, G.J. Mantzaris2, L. Peyrin-Biroulet3, S. Vermeire1

1KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID), Leuven, Belgium, 2Evaggelismos Hospital, Gastroenterology Clinic, Athens, Greece, 3Nancy University Hospital, Université de Lorraine, Inserm U954 and Department of Gastroenterology, Nancy, France

Associated factors *(cut-off derived from ROC analysis)HR95% CIp (Log-Rank)
Age at diagnosis < 22 years*1.61.1–2.40.017
Age at start of anti-TNF therapy < 32 years*1.71.1–2.40.007
Disease duration from diagnosis to start of anti-TNF therapy < 3 years*21.4–3< 0.001
Albumin at baseline < 40 g/L*3.31.8–6< 0.001
CRP at baseline > 5 mg/L*3.21.6–6.5< 0.001
Acute severe colitis for patients with UC31.8–5.3< 0.001
Active smoking at start of anti-TNF therapy1.70.9–2.80.053

DOP061.

Pharmacokinetic considerations for optimising dosing regimens of infliximab in patients with Crohn's disease

Authors:

H. Andersson1,2, A. Keunecke1, A. Eser3, W. Huisinga4, W. Reinisch3, C. Kloft1, 1Freie Universitaet Berlin, Dept. Clinical Pharmacy and Biochemistry, Berlin, Germany, 2Graduate Research Training Program PharMetrX, Freie Universitaet Berlin, Berlin, Germany, 3Medical University of Vienna, Dept. for Gastroenterology and Hepatology, Vienna, Austria, 4Universitaet Potsdam, Institute of Mathematics, Potsdam, Germany

DOP061

Prospective,Observational Study of the Therapeutic Management of Mild to Moderate Ulcerative Colitis (Observatoire Prospectif, longiTudinal dans la prise en charge de la rectocolite héMorragiqUe légère à Modérée, OPTIMUM): follow-up at 2 years

Authors:

S. Nahon1, G. Bonnaud2, N. Mammar*3

1Centre Hospitalier Le Raincy, Gastroenterology, Montfermeil, France, 2Clinique des Cèdres, Gatroenterology, Cornebarrieu, France, 3Ferring Pharmaceuticals France, Medical, Gentilly, France

DOP062.

Predictors of formation of antibodies to infliximab (ATI) and secondary loss of response in IBD patients treated with infliximab

Authors:

B. Ungar1, U. Kopylov1, M. Yavzori1, E. Fudim1, O. Picard1, A. Lahat1, B. Avidan1, A. Lang1, B. Weiss2, Y. Chowers3, R. Eliakim1, S. Ben-Horin1, 1Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel, 2Chaim Sheba Medical Center Tel-Hashomer, Edmond & Lily Safra Children's Hospita, Ramat Gan, Israel, 3Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Institute of Technology, Gastroenterology department, Haifa, Israel

DOP062

Environmental risk factors in pediatric IBD according to the hygiene hypothesis: A case-control study

Authors:

C. Strisciuglio*, F.P. Giugliano, M. Martinelli, L. Greco, S. Cenni, A. Staiano, E. Miele

University Federico II, Department of Translational and Medical Science, Section of Pediatrics, Naples, Italy

DOP063.

Biomarker panel for prediction of mucosal healing in patients with Crohn's disease under infliximab therapy

Authors:

M. de Bruyn1,2, T. Bessissow3, T. Billiet2, I. Cleynen2, R. Kirkland4, X. Liu4, S. Hauenstein4, K. Drake4, S. Singh4, M. Ferrante2, P. Rutgeerts2, G. Van Assche2, I. Arijs2, G. Opdenakker1, S. Vermeire2, 1Rega Institute for Medical Research, Laboratory of Immunobiology, Microbiology and Immunology, Leuven, Belgium, 2KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for GastroIntestinal Disorders (TARGID), Leuven, Belgium, 3McGill University, Division of Gastroenterology, Montreal Quebec, Canada, 4Prometheus Laboratories, Department of Research and Development, San Diego, United States

DOP063

What is stricturing Crohn's Disease: Comparison of clinical outcome between radiological and endoscopic stricture?

Authors:

R. Mao*, B.-l. Chen, Y. He, Z.-r. Zeng, M.-h. Chen

First Affiliated Hospital of Sun Yat-Sen University, Department of Gastroenterology, Guangzhou, China